Evidence map›Paper›PMID 39136505›Full record

ArticleCurrent topics in medicinal chemistry2024

Evaluation of Thiazolidine Derivatives with Potential Anti-ZIKV Activity.

Sayonara Maria Calado Gonçalves, Lília Vieira Galdino, Morganna Costa Lima, José Arion da Silva Moura, Douglas Carvalho Francisco Viana, Michelle Melgarejo da Rosa, Luiz Felipe Gomes Rebello Ferreira, Marcelo Zaldini Hernandes, Michelly Cristiny Pereira, Moacyr Jesus Barreto de Melo Rêgo and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current topics in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sayonara Maria Calado GonçalvesTherapeutic Innovation Research Center, Federal University of Pernambuco, Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
Lília Vieira GaldinoTherapeutic Innovation Research Center, Federal University of Pernambuco, Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
Morganna Costa LimaDepartment of Virology and Experimental Therapy, Aggeu Magalhães Institute, Oswaldo Cruz Foundation / FIOCRUZ, Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
José Arion da Silva MouraPharmaceutical Planning and Synthesis Laboratory, Federal University of Pernambuco Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
Douglas Carvalho Francisco VianaPharmaceutical Planning and Synthesis Laboratory, Federal University of Pernambuco Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
Michelle Melgarejo da RosaTherapeutic Innovation Research Center, Federal University of Pernambuco, Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
Luiz Felipe Gomes Rebello FerreiraDepartment of Pharmaceutical Sciences, Federal University of Pernambuco, Av. Prof. Artur de Sá, Recife-PE, 50740-521, Brazil.
Marcelo Zaldini HernandesDepartment of Pharmaceutical Sciences, Federal University of Pernambuco, Av. Prof. Artur de Sá, Recife-PE, 50740-521, Brazil.
Michelly Cristiny PereiraTherapeutic Innovation Research Center, Federal University of Pernambuco, Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
Moacyr Jesus Barreto de Melo RêgoTherapeutic Innovation Research Center, Federal University of Pernambuco, Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
Ivan da Rocha PittaPharmaceutical Planning and Synthesis Laboratory, Federal University of Pernambuco Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
Rafael de Oliveira FrançaDepartment of Virology and Experimental Therapy, Aggeu Magalhães Institute, Oswaldo Cruz Foundation / FIOCRUZ, Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
Marina Galdino da Rocha PittaPharmaceutical Planning and Synthesis Laboratory, Federal University of Pernambuco Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.
Maira Galdino da Rocha PittaTherapeutic Innovation Research Center, Federal University of Pernambuco, Av. Moraes Rego, 1235, Recife, 50670-901, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn this study, we have synthesized 19 Thiazolidine (TZD) derivatives to investigate their potential anti-ZIKV effects.

methodsNineteen thiazolidine derivatives were synthesized and evaluated for their cytotoxicity and antiviral activity against the ZIKA virus.

resultsAmong them, six demonstrated remarkable selectivity against the ZIKV virus, exhibiting IC50 values of <5μM, and the other compounds did not demonstrate selectivity for the virus. Interestingly, several derivatives effectively suppressed the replication of ZIKV RNA copies, with derivatives significantly reducing ZIKV mRNA levels at 24 hours post-infection (hpi). Notably, two derivatives (ZKC-4 and -9) stood out by demonstrating a protective effect against ZIKV cell entry. Informed by computational analysis of binding affinity and intermolecular interactions within the NS5 domain's N-7 and O'2 positions, ZKC-4 and FT-39 displayed the highest predicted affinities. Intriguingly, ZKC-4 and ZKC-9 derivatives exhibited the most favorable predicted binding affinities for the ZIKV-E binding site.

conclusionThe significance of TZDs as potent antiviral agents is underscored by these findings, suggesting that exploring TZD derivatives holds promise for advancing antiviral therapeutic strategies.

Indexed as

Antiviral AgentsThiazolidinesZika VirusAnimalsChlorocebus aethiopsDose-Response Relationship, DrugHumansMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipVero CellsVirus ReplicationAntiviral AgentsThiazolidinesAntiviral activityChemical synthesisDockingRNA expression.Thiazolidine derivativesZika virus

Identifiers

PMID39136505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.